University of North Dakota

UND Scholarly Commons
Physician Assistant Scholarly Project Posters

Department of Physician Studies

2014

New Age Anticoagulants: A Safer and More
Effective Alternative to Warfarin?
Benjamin Johnson
University of North Dakota

Follow this and additional works at: https://commons.und.edu/pas-grad-posters
Part of the Cardiovascular Diseases Commons
Recommended Citation
Johnson, Benjamin, "New Age Anticoagulants: A Safer and More Effective Alternative to Warfarin?" (2014). Physician Assistant
Scholarly Project Posters. 122.
https://commons.und.edu/pas-grad-posters/122

This Poster is brought to you for free and open access by the Department of Physician Studies at UND Scholarly Commons. It has been accepted for
inclusion in Physician Assistant Scholarly Project Posters by an authorized administrator of UND Scholarly Commons. For more information, please
contact zeineb.yousif@library.und.edu.

New Age Anticoagulants: A Safer and More Effective Alternative to Warfarin?
Benjamin Johnson, PA-S
Physician Assistant Program, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND 58012-9037 www.med.und.nodak.edu

Abstract

Research Questions

Atrial fibrillation is the most common sustained heart rhythm
in the United States with estimated prevalence rates of
8.8/100 (Wolf, Abbott, & Kannel, 1991). The largest risk
for patients with atrial fibrillation is that of ischemic stroke
from embolization of an atrial clot, thus the long standing
treatment for this arrhythmia is aggressive anticoagulation.
For decades this has been accomplished with the use of
warfarin, however, the increased risk of hemorrhage
combined with the inconvenience of weekly blood testing
has prompted the development of potentially safer and
more effective alternatives. A systematic review of the
literature identified studies that examined the safety and
efficacy of direct thrombin and factor Xa inhibitors
compared with traditional warfarin therapy. It was found
that the new anticoagulants reduce the incidence of stroke
and thromboembolism without increasing the risk of major
hemorrhage when compared to warfarin. This provides
health care providers another option to safely anticoagulate patients diagnosed with non-valvular atrial
fibrillation without the burden of PT/INR monitoring.

• In patients with non-valvular atrial fibrillation, are the novel,
oral anticoagulants a safer and more effective option for
the prevention of stroke and systemic embolism?
• In patients that are anticoagulated with any novel
anticoagulant, is there a reversal agent available in the
event of major trauma, bleeding, or the need for surgery?
• Are novel anticoagulants a cost effective option compared
to warfarin in patients with non-valvular atrial fibrillation?

Introduction
• Atrial fibrillation is the most common sustained heart
rhythm in the United States
• Largest risk for patients with atrial fibrillation is that of
ischemic stroke from embolization of an atrial clot.
• Many food-drug and drug-drug interactions that can
greatly influence the pharmacodynamics of warfarin
leading to an extremely variable dose response curve,
and a constant need for laboratory monitoring to ensure
adequate anticoagulation
• Several large, phase III, randomized controlled trials that
have investigated the safety and efficacy of these newer
anticoagulants compared to traditional warfarin therapy

Statement of the Problem
• Warfarin has long been recognized as an effective
therapy to prevent the occurrence of stroke and systemic
embolism; however, the risk for bleeding, the variable
dose-response curve, and the inconvenience of routine
monitoring have prompted the development of safer, more
effective alternatives.

Applicability to Clinical
Practice
• The issues of cost, safety, and efficacy must be continually
investigated by researchers and evaluated by providers in
order to optimize outcomes for any patients requiring
anticoagulation.
• The use of any novel anticoagulant or warfarin is clearly
better than the avoidance of any anticoagulation in
patients with atrial fibrillation
• Consideration should be given to individual patients stroke
and bleeding risk factors, potential financial burden,
desired clinical effect, and patient/family concerns prior to
initiation or alteration of anticoagulation.

Literature Review
• Primary end point of stroke or systemic embolism was
lower with novel anticoagulants compared with warfarin
• Risk of death from any cause was lower with all novel
anticoagulants than with warfarin
• Significant reduction in hemorrhagic stroke with novel
anticoagulants compared to warfarin

Table 1. Main Study Characteristics
Study
Drug
No. of Patients Masking
Test
Analysis (Primary Outcome) Follow-up mo.
RE-LY
Dabigatran
12098
Open label Noninferiority
ITT
300
ROCKET AF Rivaroxaban
14264
Double blind Noninferiority
ITT
20
ARISTOTLE Apixaban
18201
Double blind Noninferiority
ITT
10
Abbreviations: ARISTOTLE, Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation; ITT, intention to treat; RE-LY, Randomized
Evaluation of Long-Term Anticoagulant Therapy; ROCKET AF, An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of
a

Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation. RE-LY trial included 18113 patients;
there were 6015 patients excluded because they belonged to the low-dose study branch.

Discussion
• Currently no laboratory test to monitor the
effects of any novel anticoagulant.
• In patients with renal insufficiency, half life of
drug is lengthened
• No antidote to counteract the effects of direct
thrombin or factor Xa inhibitors.
• All authors indicated the need for an adequately
powered head to head study of direct thrombin
inhibitors versus factor Xa inhibitors.
• Current literature indicates cost effectiveness
but still many more questions than answers.

Table 2. Baseline Characteristics of the Patients
Characteristics
Male (%)
Age (y)
Aspirin at entry (%)
Vitamin K antagonist at entry (%)
Long-term vitamin K antagonist therapy (%)
Risk factors for stroke ≥3 (%)
Previous stroke, TIA, or both (%)
Previous stroke, TIA, or embolism (%)
Hypertension (%)
Diabetes (%)
LVD or heart failure (%)

RE-LY
ROCKET AF
ARISTOTLE
Dabigatran Warfarin Rivaroxaban Warfarin Apixaban Warfarin
63.2
63.2
60.3
60.3
60.5
65
71.5
71.6
73
73
70
70
38.7
40.6
36.3
36.3
31.3
30.5
62.3
62.5
50.2
48.6
57.1
57.2
32.6
32.1
87
86.9
30.2
30.2
20.3
19.8
54.9
54.6
19.2
19.7
78.9
78.9
90.3
90.8
87.3
87.6
23.1
23.4
40.4
39.5
25
24.9
31.8
31.9
62.6
62.6
35.5
35.4

Abbreviations: ARISTOTLE, Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation; LVD, left ventricular
dysfunction; RE-LY, Randomized Evaluation of Long-Term Anticoagulant Therapy; ROCKET AF, An Efficacy and Safety Study of
Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients with NonValvular Atrial Fibrillation; TIA, transient ischemic accident
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